These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39066427)

  • 1. Structural Assessment of
    Roe SK; Zhu T; Slepenkin A; Berges A; Fairman J; de la Maza LM; Massari P
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066427
    [No Abstract]   [Full Text] [Related]  

  • 2. Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the
    Tifrea DF; Pal S; Fairman J; Massari P; de la Maza LM
    NPJ Vaccines; 2020; 5(1):37. PubMed ID: 32411400
    [No Abstract]   [Full Text] [Related]  

  • 3. Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens.
    Madico G; Gursky O; Fairman J; Massari P
    Vaccines (Basel); 2017 Dec; 6(1):. PubMed ID: 29295593
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis.
    Su H; Morrison RP; Watkins NG; Caldwell HD
    J Exp Med; 1990 Jul; 172(1):203-12. PubMed ID: 1694217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to Variable Domain 4 Linear Epitopes of the
    Collar AL; Linville AC; Core SB; Wheeler CM; Geisler WM; Peabody DS; Chackerian B; Frietze KM
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968007
    [No Abstract]   [Full Text] [Related]  

  • 6. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.
    Cheng C; Pal S; Tifrea D; Jia Z; de la Maza LM
    Microbes Infect; 2014 Mar; 16(3):244-52. PubMed ID: 24291713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of neutralization of Chlamydia trachomatis infection by high avidity monoclonal antibodies to surface-exposed major outer membrane protein variable domain IV.
    Degn LLT; Bech D; Christiansen G; Birkelund S
    Mol Immunol; 2023 Nov; 163():163-173. PubMed ID: 37801817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection.
    Wang L; Cai Y; Xiong Y; Du W; Cen D; Zhang C; Song Y; Zhu S; Xue X; Zhang L
    Oncotarget; 2017 May; 8(20):33241-33251. PubMed ID: 28402260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.
    Karunakaran KP; Yu H; Jiang X; Chan Q; Moon KM; Foster LJ; Brunham RC
    Vaccine; 2015 Apr; 33(18):2159-66. PubMed ID: 25738816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation.
    Hepler RW; Nahas DD; Lucas B; Kaufhold R; Flynn JA; Galli JD; Swoyer R; Wagner JM; Espeseth AS; Joyce JG; Cook JC; Durr E
    Protein Sci; 2018 Nov; 27(11):1923-1941. PubMed ID: 30144190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus surface antigen as delivery vector can enhance Chlamydia trachomatis MOMP multi-epitope immune response in mice.
    Zhu S; Feng Y; Rao P; Xue X; Chen S; Li W; Zhu G; Zhang L
    Appl Microbiol Biotechnol; 2014 May; 98(9):4107-17. PubMed ID: 24458565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination of koalas with a recombinant Chlamydia pecorum major outer membrane protein induces antibodies of different specificity compared to those following a natural live infection.
    Kollipara A; Polkinghorne A; Beagley KW; Timms P
    PLoS One; 2013; 8(9):e74808. PubMed ID: 24086379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant expression of Chlamydia trachomatis major outer membrane protein in E. Coli outer membrane as a substrate for vaccine research.
    Wen Z; Boddicker MA; Kaufhold RM; Khandelwal P; Durr E; Qiu P; Lucas BJ; Nahas DD; Cook JC; Touch S; Skinner JM; Espeseth AS; Przysiecki CT; Zhang L
    BMC Microbiol; 2016 Jul; 16(1):165. PubMed ID: 27464881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.
    Yu H; Karunakaran KP; Jiang X; Brunham RC
    Vaccine; 2014 Aug; 32(36):4672-80. PubMed ID: 24992718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.
    Bøje S; Olsen AW; Erneholm K; Agerholm JS; Jungersen G; Andersen P; Follmann F
    Immunol Cell Biol; 2016 Feb; 94(2):185-95. PubMed ID: 26268662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model.
    Jiang P; Cai Y; Chen J; Ye X; Mao S; Zhu S; Xue X; Chen S; Zhang L
    Vaccine; 2017 May; 35(23):3096-3103. PubMed ID: 28456528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human antibody signatures towards the Chlamydia trachomatis major outer membrane protein after natural infection and vaccination.
    Rosenkrands I; Olsen AW; Knudsen S; Dehari N; Juel HB; Cheeseman HM; Andersen P; Shattock RJ; Follmann F
    EBioMedicine; 2024 Jun; 104():105140. PubMed ID: 38744110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.
    Olsen AW; Rosenkrands I; Holland MJ; Andersen P; Follmann F
    NPJ Vaccines; 2021 Apr; 6(1):58. PubMed ID: 33875654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in
    Kiekens C; Morré SA; Vanrompay D
    Microorganisms; 2024 Jun; 12(6):. PubMed ID: 38930578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.